Short Interest in Hookipa Pharma Inc (NASDAQ:HOOK) Decreases By 85.7%

Hookipa Pharma Inc (NASDAQ:HOOK) was the recipient of a large drop in short interest during the month of June. As of June 30th, there was short interest totalling 64,800 shares, a drop of 85.7% from the June 15th total of 453,000 shares. Currently, 0.8% of the shares of the stock are sold short. Based on an average trading volume of 88,300 shares, the days-to-cover ratio is currently 0.7 days.

Institutional Investors Weigh In On Hookipa Pharma

A hedge fund recently bought a new stake in Hookipa Pharma stock. Virtu Financial LLC purchased a new stake in shares of Hookipa Pharma Inc (NASDAQ:HOOK) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 43,021 shares of the company’s stock, valued at approximately $31,000. 63.88% of the stock is currently owned by institutional investors.

Hookipa Pharma Stock Up 11.6 %

Shares of HOOK traded up $0.64 during mid-day trading on Thursday, hitting $6.14. 116,119 shares of the company’s stock traded hands, compared to its average volume of 72,423. Hookipa Pharma has a 1 year low of $4.10 and a 1 year high of $11.30. The firm has a market capitalization of $607.55 million, a P/E ratio of -12.28 and a beta of 0.81. The business’s 50-day moving average price is $7.44 and its 200-day moving average price is $7.42.

Hookipa Pharma (NASDAQ:HOOK) last posted its earnings results on Thursday, May 9th. The company reported $1.20 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.20) by $2.40. The firm had revenue of $36.60 million for the quarter, compared to analysts’ expectations of $3.20 million. Hookipa Pharma had a negative return on equity of 33.33% and a negative net margin of 88.73%. During the same period in the previous year, the firm earned ($2.70) earnings per share. Sell-side analysts anticipate that Hookipa Pharma will post -0.46 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the company. HC Wainwright boosted their target price on Hookipa Pharma from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, June 5th. Royal Bank of Canada reiterated an “outperform” rating and issued a $50.00 price objective on shares of Hookipa Pharma in a research report on Tuesday, May 21st.

About Hookipa Pharma

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.